Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer

Cell Cycle

Volumn 12, Issue 13, 2013, Pages 1999-2010

  Wang, Chunmei ^a   Cigliano, Antonio ^b   Delogu, Salvatore ^b   Armbruster, Julia ^b   Dombrowski, Frank ^b   Evert, Matthias ^b   Chen, Xin ^a   Calvisi, Diego F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

AKT; Liver cancer; Mouse models; mTOR; Rapamycin; Ras

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GLYCOLYSIS; LIPOGENESIS; LIVER CARCINOGENESIS; MOUSE; NONHUMAN; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANIMALIA; MUS;

EID: 84879771957     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25099     Document Type: Article

References (39)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-27; PMID:21992124; http://dx.doi.org/10.1056/NEJMra1001683
2. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-2; PMID:21374666; http://dx.doi.org/10.1002/hep.24199
3. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011; 140:1071-83; PMID:21147110; http://dx.doi.org/10.1053/j.gastro.2010.12.006
4. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10:8421-5; PMID:15623621; http://dx.doi.org/10.1158/1078-0432.CCR-04-0941
5. Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008; 135:1322-32; PMID:18722373; http://dx.doi.org/10.1053/j.gastro.2008.07.012
6. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135(83 e1-11):1972-83, e1-11; PMID:18929564; http://dx.doi.org/10.1053/j. gastro.2008.08.008
7. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130:1117-28; PMID:16618406; http://dx.doi.org/10.1053/j. gastro.2006.01.006
8. Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, et al. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of Rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology 2012; 55:833-45; PMID:21993994; http://dx.doi.org/10.1002/hep.24736
9. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-44; PMID:19644473; http://dx.doi.org/10.1038/nrd2926
10. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93; PMID:22500797; http://dx.doi.org/10.1016/j.cell.2012.03. 017
11. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011; 11:289-301; PMID:21430697; http://dx.doi.org/10.1038/nrc3037
12. Kudo M. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. Dig Dis 2011; 29:273-7; PMID:21829017; http://dx.doi.org/10.1159/ 000327558
13. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 2004; 101:2082-7; PMID:14769918; http://dx.doi.org/10.1073/pnas.0308617100
14. Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 2009; 9:247-61; PMID:19192962; http://dx.doi.org/10.1586/14737140.9.2.247
15. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009; 2:pe24; PMID:19383975; http://dx.doi.org/10.1126/scisignal.267pe24
16. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121:1231-41; PMID:21490404; http://dx.doi.org/10.1172/JCI44145
17. Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, Rapamycin-resistance and cancer therapy. Cell Cycle 2009; 8:567-72; PMID:19197153; http://dx.doi.org/10.4161/cc.8.4.7659
18. Carracedo A, Baselga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008; 7:3805-9; PMID:19098454; http://dx.doi.org/10.4161/cc.7.24.7244
19. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008; 105:17414-9; PMID:18955708; http://dx.doi.org/10.1073/pnas.0809136105
20. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010; 17:249-61; PMID:20227039; http://dx.doi.org/10.1016/j.ccr.2010.01.021
21. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26:1932-40; PMID:17001314; http://dx.doi.org/10.1038/sj.onc.1209990
22. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166:213-23; PMID:15249583; http://dx.doi.org/10.1083/jcb.200403069
23. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, et al. Mammalian target of Rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111:379-82; PMID:17878402; http://dx.doi.org/10.1182/blood-2007-03- 080796
24. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-74; PMID:18725988
25. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308; PMID:17384584; http://dx.doi.org/10.1038/nrc2109
26. Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, et al. Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology 2008; 47:1200-10; PMID:18214995; http://dx.doi.org/10.1002/hep.22169
27. Lee SA, Ladu S, Evert M, Dombrowski F, De Murtas V, Chen X, et al. Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. Hepatology 2010; 52:506-17; PMID:20683950; http://dx.doi.org/10.1002/hep.23681
28. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, et al. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 2011; 54:311-9; PMID:21067840; http://dx.doi.org/10.1016/j.jhep.2010.06.036
29. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of premalignant hepatocytes limits liver cancer development. Nature 2011; 479:547-51; PMID:22080947; http://dx.doi.org/10.1038/ nature10599
30. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8:179-83; PMID:16169463; http://dx.doi.org/10.1016/j.ccr.2005.08.008
31. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118:3051-64; PMID:18725989
32. Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett 2012; 319:1-7; PMID:22261336; http://dx.doi.org/10.1016/j. canlet.2012.01.005
33. Huynh H. AZD6244 (ARRY-142886) enhances the antitumor activity of Rapamycin in mouse models of human hepatocellular carcinoma. Cancer 2010; 116:1315-25; PMID:20101735; http://dx.doi.org/10.1002/cncr.24863
34. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. Ras pathway activation in hepatocellular carcinoma and antitumoral effect of combined sorafenib and Rapamycin in vivo. J Hepatol 2009; 51:725-33; PMID:19665249; http://dx.doi.org/10.1016/j.jhep.2009.03.028
35. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, et al. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 2011; 10:3003-15; PMID:21869603; http://dx.doi.org/10.4161/cc.10.17.17119
36. Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008; 27:4086-95; PMID:18332865; http://dx.doi.org/10.1038/onc.2008.49
37. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci USA 2013; 110:4015-20; PMID:23431193; http://dx.doi.org/10.1073/pnas. 1216013110
38. Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011; 42:36-49; PMID:21474066; http://dx.doi.org/10.1016/j.molcel.2011.02.020
39. Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget 2011; 2:610-26; PMID:21881167